Raja Rajeswari Kamisetti, Moses Mekala, Sudhakar Muvvala, Durga Bhavani Penmatsa


As precision of dosing and patient compliance become an important prerequisite for a long-term treatment of Tourette’s syndrome there is a need to develop formulation for this drug, which overcomes problems such as difficulty in swallowing, inconvenience in administration while travelling and patient’s acceptability. The present work was undertaken with a view to develop a fast dissolving tablets of Pimozide  using Kyron T-314 as super-disintegrant along with Avicel PH 102 as diluent by response surface method using direct compression. Drug-excipient compatibility studies were confirmed by FTIR Spectroscopy. The tablets were evaluated for hardness, friability, weight variation, wetting time, disintegration time and uniformity of content and invitro dissolution. Based on evaluating parameters, formulation prepared by using 4.5% Kyron T-314 with 11.5% Avicel PH-102 was selected as optimized formulation and Formulation (F3) had disintegration time of 7.63±0.25s. and percentage cumulative drug release of   81.60 after 10min. The formulations were further studied and confirmed for their stability. Hence it was concluded that direct compression using Kyron T-314 superdisintegrant and Avicel PH 102 was simple and economic technique which can be used for formulation of fast dissolving tablets of Pimozide.

Key word: Pimozide, Tourette’s syndrome, fast dissolving tablets, Kyron T 314, direct compression 

Full Text:



Biradar SS., Bhagavati ST., Kuppasad IJ. 2006. Fast dissolving drug delivery systems: A brief overview. Int J Pharmacol., v.24(2), p.1-7,

Bi YX., Sunada H., Yonezawa Y., Danjo K. 1999. Evaluation of rapidly disintegrating tablets by direct compression method. Drug Develop Ind Pharm., v.25, p. 571-581,

Chaudhari PD., Chaudhari SP., Kohle SR., Dave KV, More DM. 2005. Formulation and evaluation of fast dissolving tablets of famotidine. Ind. Drugs.,v.42, p.641-649

Clare ME., Hugh E., Rickard. 2011. Treatment Strategies for tics in Tourette Syndrome. Ther Adv. Neurol Disord., v.4(1), 25-45

Dobetti L. 2001. Fast-melting tablets: Developments and technologies. Pharm Technol N Am.,V. 12(9), p.44–50.

Logan FA., Herrington RN., Mackie MM., Rubin PC., 1982 Pimozide: adverse reaction and prolonged half-life. Brit J Psyc.,v. 140, p.433-4

Fog R., Pakkenberg H., 1980. Theoritical and Clinical aspects of the Tourettic Syndrome (chronic multiple tic).J.NeuralTransm., v.16, p.211-5,

Habib W., Khankari R., Hontz J., 2000. Fast-Dissolve Drug Delivery System. Crit Rev Ther Drug Carrier Syst., v.17, p.61-72,

James FL., 2002. Toutte’s Syndrome. The Lancet., V. 360, P. 1577–158

Kane Jm., Eerdekens M., Lindenmayer JP., 2003. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am. J Psychiatry., v.160: p.1125–32,

Sadhana RS., Minakshi VK., Somshekhar S., Nityanand Z., 2013. Formulation and Evaluation of Atenolol Orodispersible tablets by Phase Transition technology., v. 5: 13: p.604-609,

Seeman P. 2002. Atypical antipsychotics: mechanism of action. Can J Psychiatry., v. 47(1): p.27-38



  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:

analytics View My Stats